From: "Louise Binder" <louise.binder@sympatico.ca>
Date: Tue, 22 Aug 2006

I will be registering for the meeting.

Regarding the discussion Guide you sent I am generally satisfied with much
of our present process except in a few araeas. I do not think that the u.S.
or any other country that has no prce controls whatsoever should be allowed
to be in our basket of comnparator drugs for any purpose.

I think a comparison of drugs of " moderate" versus "little or no therapeutic improvement " should be based on appropriate clinicathi nk the
board should look past the ATP to calculate 1 trials and also quality of
life indicators from consumers. Sometimes a drug that is of little value to
anyone else works well for one segment of the population taking it or even
individuals.

I think that ATP should be based on more than the total revenues from the
sales for all P/Tand all classes of customers. This will be a good discussion for consultation.

I will be away until mid-September if you need clarification of these comments.